226 related articles for article (PubMed ID: 27287872)
21. SOX9 expression predicts relapse of stage II colon cancer patients.
Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
[TBL] [Abstract][Full Text] [Related]
22. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of tissue transglutaminase 2 in colon carcinoma.
Fernández-Aceñero MJ; Torres S; Garcia-Palmero I; Díaz Del Arco C; Casal JI
Virchows Arch; 2016 Dec; 469(6):611-619. PubMed ID: 27620315
[TBL] [Abstract][Full Text] [Related]
24. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP
J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406
[TBL] [Abstract][Full Text] [Related]
25. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
26. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
[TBL] [Abstract][Full Text] [Related]
27. Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma.
Wang XQ; Tang ZX; Yu D; Cui SJ; Jiang YH; Zhang Q; Wang J; Yang PY; Liu F
Oncotarget; 2016 Feb; 7(8):8823-38. PubMed ID: 26741506
[TBL] [Abstract][Full Text] [Related]
28. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G
Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288
[TBL] [Abstract][Full Text] [Related]
29. Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.
Bullock MD; Pickard K; Mitter R; Sayan AE; Primrose JN; Ivan C; Calin GA; Thomas GJ; Packham GK; Mirnezami AH
Oncotarget; 2015 Mar; 6(9):7262-79. PubMed ID: 25788261
[TBL] [Abstract][Full Text] [Related]
30. Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival.
Fink SP; Myeroff LL; Kariv R; Platzer P; Xin B; Mikkola D; Lawrence E; Morris N; Nosrati A; Willson JK; Willis J; Veigl M; Barnholtz-Sloan JS; Wang Z; Markowitz SD
Oncotarget; 2015 Oct; 6(31):30500-15. PubMed ID: 26437221
[TBL] [Abstract][Full Text] [Related]
31. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
33. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
34. A robust gene signature for the prediction of early relapse in stage I-III colon cancer.
Dai W; Li Y; Mo S; Feng Y; Zhang L; Xu Y; Li Q; Cai G
Mol Oncol; 2018 Apr; 12(4):463-475. PubMed ID: 29377588
[TBL] [Abstract][Full Text] [Related]
35. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse.
Lu CY; Uen YH; Tsai HL; Chuang SC; Hou MF; Wu DC; Juo SH; Lin SR; Wang JY
Br J Cancer; 2011 Mar; 104(7):1178-84. PubMed ID: 21343933
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
38. Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer.
Okuyama T; Sameshima S; Takeshita E; Mitsui T; Noro T; Ono Y; Noie T; Ban S; Oya M
BMC Cancer; 2020 Sep; 20(1):842. PubMed ID: 32883261
[TBL] [Abstract][Full Text] [Related]
39. Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer.
Konishi K; Yamamoto H; Mimori K; Takemasa I; Mizushima T; Ikeda M; Sekimoto M; Matsuura N; Takao T; Doki Y; Mori M
Cancer Sci; 2010 Oct; 101(10):2269-77. PubMed ID: 20825414
[TBL] [Abstract][Full Text] [Related]
40. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer.
Wong JC; Chan SK; Schaeffer DF; Sagaert X; Lim HJ; Kennecke H; Owen DA; Suh KW; Kim YB; Tai IT
Clin Cancer Res; 2011 Jun; 17(12):4167-76. PubMed ID: 21531813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
